Manuela Colafigli

Summary

Country: Italy

Publications

  1. doi request reprint Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010
    M Colafigli
    Institute of Clinical Infectious Diseases, Catholic University of S Heart, Rome, Italy
    Clin Microbiol Infect 18:E299-304. 2012
  2. doi request reprint Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen
    M Colafigli
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    HIV Med 9:172-9. 2008
  3. doi request reprint Long-term follow-up of nevirapine-treated patients in a single-centre cohort
    Manuela Colafigli
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    HIV Med 10:461-9. 2009
  4. doi request reprint Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir an
    Simona Di Giambenedetto
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    J Antimicrob Chemother 68:1364-72. 2013
  5. doi request reprint Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1
    Laura Bracciale
    Institute of Clinical of Infectious Disease, Catholic University of Sacred Heart, Rome, Italy
    AIDS Res Hum Retroviruses 25:261-7. 2009
  6. ncbi request reprint Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study
    Simona Di Giambenedetto
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 12:835-9. 2007
  7. ncbi request reprint Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Roma, 00168, Italy
    J Infect Dis 196:1645-53. 2007
  8. ncbi request reprint Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors
    Simona Di Giambenedetto
    Institute of Clinical Infectious DiseasesCatholic University, Rome, Italy
    Scand J Infect Dis 39:813-8. 2007
  9. pmc Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping
    Mattia C F Prosperi
    Infectious Diseases Clinic, Catholic University of Sacred Heart, Rome, Italy
    Retrovirology 7:56. 2010
  10. doi request reprint Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RAST
    Massimiliano Fabbiani
    From the Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome
    Scand J Infect Dis 46:34-45. 2014

Detail Information

Publications15

  1. doi request reprint Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010
    M Colafigli
    Institute of Clinical Infectious Diseases, Catholic University of S Heart, Rome, Italy
    Clin Microbiol Infect 18:E299-304. 2012
    ..TDR significantly declined overall and for the single drug classes. Older age independently predicted increased odds of TDR, whereas a more recent GRT, a higher HIV-RNA and C vs. B subtype predicted lower odds of TDR...
  2. doi request reprint Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen
    M Colafigli
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    HIV Med 9:172-9. 2008
    ....
  3. doi request reprint Long-term follow-up of nevirapine-treated patients in a single-centre cohort
    Manuela Colafigli
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    HIV Med 10:461-9. 2009
    ..We reviewed the safety and efficacy of nevirapine (NVP)-based therapy in all patients initiating NVP-containing combined antiretroviral therapy [cART (>or=3 drugs)] in our clinic since 1994...
  4. doi request reprint Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir an
    Simona Di Giambenedetto
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    J Antimicrob Chemother 68:1364-72. 2013
    ..To explore 48 week safety and efficacy of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression on a stable atazanavir/ritonavir-based standard triple regimen...
  5. doi request reprint Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1
    Laura Bracciale
    Institute of Clinical of Infectious Disease, Catholic University of Sacred Heart, Rome, Italy
    AIDS Res Hum Retroviruses 25:261-7. 2009
    ..The achievement of virological suppression is a strong predictor of reduced clinical progression...
  6. ncbi request reprint Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study
    Simona Di Giambenedetto
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 12:835-9. 2007
    ..We explored the evolution of genotypic drug resistance prevalence in treatment-failing patients from 1999 to 2005 in a clinical cohort...
  7. ncbi request reprint Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Roma, 00168, Italy
    J Infect Dis 196:1645-53. 2007
    ..Consensus on the interpretation of mutations in the human immunodeficiency virus (HIV)-1 reverse transcriptase (RT) gene that predict the response to didanosine treatment is needed...
  8. ncbi request reprint Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors
    Simona Di Giambenedetto
    Institute of Clinical Infectious DiseasesCatholic University, Rome, Italy
    Scand J Infect Dis 39:813-8. 2007
    ..In patients failing PIs, the interpretation of genotypic resistance to fosamprenavir may change considerably according to the different algorithms and in respect to the effect of pharmacokinetic boosting with ritonavir...
  9. pmc Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping
    Mattia C F Prosperi
    Infectious Diseases Clinic, Catholic University of Sacred Heart, Rome, Italy
    Retrovirology 7:56. 2010
    ..7% false positive rate cutoff were evaluated using viral DNA and RNA samples, compared against each other and ESTA, using Cohen's kappa, phylogenetic analysis, and area under the receiver operating characteristic (AUROC)...
  10. doi request reprint Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RAST
    Massimiliano Fabbiani
    From the Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome
    Scand J Infect Dis 46:34-45. 2014
    ..Improvements in lipid levels, quality of life measures, neuropsychological performance, and bone composition suggest good tolerability of raltegravir-based regimens. ..
  11. pmc Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study
    Mattia C F Prosperi
    Viral Immunodeficiency Unit, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    BMC Infect Dis 12:296. 2012
    ..However, its determinants are not fully understood. Aim of this study was to investigate predictors of first-line antiretroviral therapy discontinuation due to adverse events and their evolution in recent years...
  12. doi request reprint Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia
    Nicoletta Ciccarelli
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    Antivir Ther 18:153-60. 2013
    ..The objective of our study was to compare two different central nervous system penetration-effectiveness (CPE) scores for the prediction of cognitive dysfunction in HIV-infected patients...
  13. doi request reprint The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy
    Angela Marzocchetti
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    AIDS Res Hum Retroviruses 27:1299-309. 2011
    ..10; p=0.04). Knowledge of the effect of genetic determinants on dyslipidemia and lipodystrophy may prompt the investigation of potential pathogenetic mechanisms and might eventually be used for guiding individualized treatment decisions...
  14. doi request reprint HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects
    Massimiliano Fabbiani
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Largo Agostino Gemelli 8, 00168 Rome, Italy
    Vaccine 31:2914-8. 2013
    ..In conclusion, in HIV-infected patients influenza vaccination could have good efficacy in sustaining humoral response but cellular response appeared impaired...
  15. ncbi request reprint Interpretation systems for genotypic drug resistance of HIV-1
    Andrea De Luca
    Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
    Scand J Infect Dis Suppl 106:29-34. 2003
    ..Importantly, only 8 systems were intended for clinical use and 5 of these had at least partially undergone clinical validation...